» Articles » PMID: 34492401

Asthma and Comorbid Conditions-Pulmonary Comorbidity

Overview
Date 2021 Sep 7
PMID 34492401
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Pulmonary comorbidities can increase disease severity and health care costs associated with asthma management. Vocal cord dysfunction/inducible laryngeal obstruction is a common comorbidity that results from intermittent laryngeal obstruction. Patients describe distinct episodes of dyspnea that do not respond to bronchodilators. Inspiratory stridor is common. The gold standard diagnostic testing strategy is continuous laryngoscopy performed during exercise or irritant challenges. Dysfunctional breathing (DB) is an overarching term that describes conditions with a chronic change in the pattern of breathing that results in pulmonary and extrapulmonary symptoms. The prevalence of DB in asthma is up to 30%, and breathing retraining can improve symptoms and quality of life in people with DB and asthma. Asthma-chronic obstructive pulmonary disease overlap (ACO) refers to both asthmatics who develop fixed airflow obstruction after a history of exposure to smoke or biomass and patients with chronic obstructive pulmonary disease who have "asthmatic features" such as a large bronchodilator response, elevated levels of serum IgE, or peripheral eosinophil counts ≥300 per μL. Triple inhaler therapy with inhaled corticosteroid/long-acting beta-agonist/long-acting muscarinic should be considered in people with ACO and severe symptoms or frequent exacerbations. The clinical expression of bronchiectasis involves persistent mucus hypersecretion, recurrent exacerbations of infective bronchitis, incompletely reversible airflow obstruction, and lung fibrosis and can occur in up to 30% of adults with longstanding asthma. The treatable traits strategy is a useful model of care to manage the complexity and heterogeneity of asthma with pulmonary comorbidity.

Citing Articles

Prevalence of Obesity and Its Associated Comorbidities in Adults with Asthma: A Single-Center Study in Saudi Arabia.

Alghamdi A, Alwadeai K, Almeshari M, Alhammad S, Alsaif S, Alshehri W Medicina (Kaunas). 2024; 60(11).

PMID: 39596970 PMC: 11596902. DOI: 10.3390/medicina60111785.


Integrating hot topics and implementation of treatable traits in asthma.

Gibson P, McDonald V Eur Respir J. 2024; 64(6).

PMID: 39255992 PMC: 11618818. DOI: 10.1183/13993003.00861-2024.


A comparison of treatment response to biologics in asthma-COPD overlap and pure asthma: Findings from the PRISM study.

Shim J, Kim H, Kwon J, Park S, Kim S, Kim B World Allergy Organ J. 2023; 16(12):100848.

PMID: 38093952 PMC: 10716772. DOI: 10.1016/j.waojou.2023.100848.


Progress in diagnosis and treatment of difficult-to-treat asthma in children.

Zhou X, Zhang P, Tan H, Dong B, Jing Z, Wu H Ther Adv Respir Dis. 2023; 17:17534666231213637.

PMID: 38069568 PMC: 10710755. DOI: 10.1177/17534666231213637.


Bringing the treatable traits approach to primary care asthma management.

Pfeffer P, Rupani H, De Simoni A Front Allergy. 2023; 4:1240375.

PMID: 37799134 PMC: 10548136. DOI: 10.3389/falgy.2023.1240375.